Lung cancer is one of the malignant tumors with the highest incidence and mortality in the
world. The overall five-year survival rate of lung cancer is relatively lower than many leading …

Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …

Purpose To develop a radiomics signature to estimate disease-free survival (DFS) in
patients with early-stage (stage I–II) non–small cell lung cancer (NSCLC) and assess its …

Lung cancer is the leading cause of cancer-related death and the second most diagnosed
cancer for both men and women in the United States 1, 2 More than 25, 000 surgeries for …

Objectives Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous
population with disease presentation ranging from apparently resectable tumors with occult …

Lung cancer is the leading cause of cancer-related death in the United States. An estimated
219,440 new cases (116,090 men; 103,350 women) of lung and bronchus cancer were …

Background Stereotactic ablative radiotherapy (SABR) is increasingly used in the treatment
of medically inoperable early stage non-small-cell lung cancer (NSCLC). Because patterns …

Context Mediastinal nodal staging is recommended for patients with resectable non–small
cell lung cancer (NSCLC). Surgical staging has limitations, which results in the performance …

Novel molecular imaging techniques have the potential to significantly enhance the
diagnostic and therapeutic approaches for cancer treatment. For solid tumors in particular …

Increasing evidence has indicated that plenty of lncRNAs play important roles in many
critical biological processes. Developing powerful computational models to construct …